H

Horizon Therapeutics PLC
F:HPR

Watchlist Manager
Horizon Therapeutics PLC
F:HPR
Watchlist
Price: 110.2 EUR Market Closed
Market Cap: 25.3B EUR

Horizon Therapeutics PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Horizon Therapeutics PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
H
Horizon Therapeutics PLC
F:HPR
Cash from Operating Activities
$1B
CAGR 3-Years
49%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Alkermes Plc
NASDAQ:ALKS
Cash from Operating Activities
$540.7m
CAGR 3-Years
120%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Cash from Operating Activities
-$21.6m
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Prothena Corporation PLC
NASDAQ:PRTA
Cash from Operating Activities
-$188m
CAGR 3-Years
-14%
CAGR 5-Years
-20%
CAGR 10-Years
-13%
M
Mural Oncology PLC
NASDAQ:MURA
Cash from Operating Activities
-$128.5m
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Horizon Therapeutics PLC
Glance View

Market Cap
25.2B EUR
Industry
Biotechnology

Horizon Therapeutics PLC, established in 2008 and headquartered in Dublin, has carved a unique niche in the biopharmaceutical industry by focusing on researching, developing, and commercializing medicines that address rare and rheumatic diseases. The company has embraced a patient-centric approach, aiming to improve the quality of life for individuals with conditions often overlooked by larger pharmaceutical companies. This dedication has resulted in a robust portfolio of medicines, including treatments for conditions like thyroid eye disease, chronic granulomatous disease, and urea cycle disorders. Horizon Therapeutics takes pride in its ability to identify and develop orphan drugs, leveraging innovative scientific methods and strategic acquisitions to enhance its offerings. The company generates its revenue by bringing its targeted therapies to market, often focusing on diseases with unmet medical needs. Horizon's business model capitalizes on its ability to navigate the intricate regulatory landscape surrounding rare disease treatments, allowing them to secure expedited approvals and launch therapies swiftly. By deepening its engagement with healthcare providers, patients, and advocacy groups, Horizon seeks to become an indispensable partner in the therapeutic process, thus driving consistent demand for its products. This strategic alignment not only boosts sales but also fortifies its market position, enabling Horizon Therapeutics to sustain its mission of transforming patients' lives through meaningful medicine.

HPR Intrinsic Value
Not Available
H

See Also

What is Horizon Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
1B USD

Based on the financial report for Jun 30, 2023, Horizon Therapeutics PLC's Cash from Operating Activities amounts to 1B USD.

What is Horizon Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
37%

Over the last year, the Cash from Operating Activities growth was -26%. The average annual Cash from Operating Activities growth rates for Horizon Therapeutics PLC have been 49% over the past three years , 37% over the past five years .

Back to Top